These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27879191)

  • 1. Replacement of SFC-DPI with SFC-MDI exhaled through the nose improves eosinophilic chronic rhinosinusitis in patients with bronchial asthma.
    Kobayashi Y; Asako M; Yamamoto T; Yasuba H; Tomoda K; Kanda A
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):89-94. PubMed ID: 27879191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HFA-BDP Metered-Dose Inhaler Exhaled Through the Nose Improves Eosinophilic Chronic Rhinosinusitis With Bronchial Asthma: A Blinded, Placebo-Controlled Study.
    Kobayashi Y; Yasuba H; Asako M; Yamamoto T; Takano H; Tomoda K; Kanda A; Iwai H
    Front Immunol; 2018; 9():2192. PubMed ID: 30337921
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel therapeutic use of HFA-BDP metereddose inhaler for asthmatic patients with rhinosinusitis: Case series.
    Kobayashi Y; Asako M; Kanda A; Tomoda K; Yasuba H
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):914-9. PubMed ID: 25074867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study.
    Kupczyk M; Majak P; Kuna P; Asankowicz-Bargiel B; Barańska E; Dobek R; Garbicz S; Jerzyńska J; Latos A; Machowiak W; Majorek-Olechowska B; Olech-Cudzik A; Poziomkowska-Gęsicka I; Rulewicz-Warniełło M; Świderska A; Tarnowski M; Kopyto P
    Respir Med; 2021 Jan; 176():106274. PubMed ID: 33276251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual exhaled nitric oxide elevation in asthmatics is associated with eosinophilic chronic rhinosinusitis.
    Kobayashi Y; Asako M; Ooka H; Kanda A; Tomoda K; Yasuba H
    J Asthma; 2015; 52(10):1060-4. PubMed ID: 26288109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nasally exhaling budesonide/formoterol dry powder inhaled at "fast" inspiratory flow on eosinophilic chronic rhinosinusitis
.
    Hamada S; Hira D; Kobayashi Y; Yasuba H
    Int J Clin Pharmacol Ther; 2018 Nov; 56(11):539-543. PubMed ID: 30049305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study.
    Corda L; Gardenghi GG; Modina D; Montemurro LT; Novali M; Tantucci C
    Allergy Asthma Proc; 2011; 32(6):29-34. PubMed ID: 22221427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
    Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
    Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma.
    Miller DS; Yiu G; Hellriegel ET; Steinfeld J
    Allergy Asthma Proc; 2016 Jul; 37(4):291-301. PubMed ID: 27216137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
    Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG
    Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma.
    Bulac S; Cimrin A; Ellidokuz H
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of HFA-BDP for adult patients with bronchial asthma: randomized crossover study with fluticasone.
    Horiguchi T; Hayashi N; Ohira D; Torigoe H; Ito T; Hirose M; Sasaki Y; Shiga M; Miyazaki J; Kondo R; Tachikawa S
    J Asthma; 2006 Sep; 43(7):509-12. PubMed ID: 16939990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study.
    Barnes N; Price D; Colice G; Chisholm A; Dorinsky P; Hillyer EV; Burden A; Lee AJ; Martin RJ; Roche N; von Ziegenweidt J; Israel E
    Clin Exp Allergy; 2011 Nov; 41(11):1521-32. PubMed ID: 21752116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salmeterol/fluticasone through breath-actuated inhaler versus pMDI: a randomized, double-blind, 12 weeks study.
    Dhar R; Salvi S; Rajan S; Dalal S; Tikkiwal S; Bhagat R; Ahmed MM; Balki A; Jain M; Gogtay J
    J Asthma; 2015; 52(10):1065-72. PubMed ID: 26288199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Device type and real-world effectiveness of asthma combination therapy: an observational study.
    Price D; Roche N; Christian Virchow J; Burden A; Ali M; Chisholm A; Lee AJ; Hillyer EV; von Ziegenweidt J
    Respir Med; 2011 Oct; 105(10):1457-66. PubMed ID: 21612903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
    Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.